

**Induction Healthcare Group PLC**  
**("Induction", the "Company", or the "Group")**

**Block Listing Six Monthly Return**

Induction Healthcare (AIM: INHC) a leading digital health platform driving transformation of healthcare systems worldwide, makes the following six-monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

Name of applicant:	Induction Healthcare Group PLC  LEI: 213800RY96GCZQW5TP19			
Name of scheme:	The Induction Healthcare NTA Share Option Plan			
Period of return:	From:	27/07/2022	To:	26/01/2023
Number and class of securities originally admitted and the date of admission	3,500,000 ordinary shares on 26 July 2021			
Balance of unallotted securities under scheme(s) from initial application:	3,103,433			
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	Nil			
<u>Less:</u> Number of securities issued/allotted under scheme(s) during the period:	Nil			
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:	3,103,433			
<u>Contact:</u>	Louise Torr, Company Secretary louise.t@inductionhealthcare.com			

**ENQUIRIES**

**Induction**  
Christopher Samler, Executive Chair  
Paul Tambeau, Chief Operating Officer

Via Walbrook PR Ltd: induction@walbrookpr.com

**Singer Capital Markets** (Nominated Adviser and Broker)  
Philip Davies

+44 (0)20 7496 3000

**Walbrook PR Ltd**  
Paul McManus / Alice Woodings

induction@walbrookpr.com  
Mob: +44(0)7980 541 893 / +44 (0)7407 804 654

**About Induction** - [www.inductionhealthcare.com](http://www.inductionhealthcare.com)

Induction (AIM: INHC) Induction delivers a suite of software solutions through a single integrated platform that transforms care delivery. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.

Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLRNKABKQBKDKDB